Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control

The breakthrough discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) 20 years ago revolutionised the current understanding of cholesterol homeostasis. Genetic studies have shown that gain-of-function mutations in PCSK9 lead to elevated LDL cholesterol and increased risk of atheroscler...

Descripción completa

Detalles Bibliográficos
Autores principales: Rikhi, Rishi, Shapiro, Michael D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2023
Materias:
Dyslipidaemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345936/
https://www.ncbi.nlm.nih.gov/pubmed/37456766
http://dx.doi.org/10.15420/ecr.2023.14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345936/
https://www.ncbi.nlm.nih.gov/pubmed/37456766
http://dx.doi.org/10.15420/ecr.2023.14

Ejemplares similares